Actelion Robin

Actelion UK appoints Robin Bhattacherjee General Manager

pharmafile | November 4, 2009 | Appointment | Research and Development, Sales and Marketing Actelion, appointment, research and development, sales and marketing 

Actelion UK has appointed Robin Bhattacherjee general manager for the UK and Ireland. He will be based at the company’s UK office in Chiswick, London.

Prior to this role, Robin was executive director at CV Therapeutics (CVT) Europe where he was responsible for establishing the European office for CV Therapeutics.

He also spearheaded the strategic development and launch of a range of specialist cardiovascular products, and identified and established European marketing partnerships, before CVT was acquired by Gilead Sciences in 2009.

With a pharmaceutical career history spanning over two decades, Robin brings a wealth of knowledge and experience to Actelion UK from several managerial roles, which includes head of cardiovascular marketing at Sanofi-Synthélabo UK and marketing director within Bayer’s Global Strategic Marketing Group.

Robin commented: “This role attracted me from the very outset and I am privileged to have the opportunity to lead the UK team of such an innovative global pharmaceutical company.

“Actelion Pharmaceuticals is a science-based company committed to researching and developing treatments for rare orphan diseases in areas of high unmet clinical need such as pulmonary arterial hypertension, Gaucher’s and Niemann-Pick type C. I look forward to supporting Actelion’s continued commitment to these important therapy areas; to the specialist physicians, healthcare professionals and patient group communities”.

Actelion Pharmaceuticals UK is the British arm of Actelion Ltd, a biopharmaceutical company with its corporate headquarters based in Allschwil/Basel, Switzerland. Actelion Ltd focuses on the discovery, development and marketing of drugs for a high unmet medical need.

Related Content

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide …

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

Latest content